

AMENDMENT

In the Claims:

Please cancel claims 24-32 without prejudice or disclaimer. The applicants reserve the right to pursue these canceled claims in a continuation or divisional patent application. Also, please replace claims 14-22 with the following replacement claims.

14. (Amended) A method for treating a sensitized T cell-mediated disease, which comprises administering to a patient in need thereof a pharmaceutical composition comprising an antibody directed against interleukin-6 (IL-6) receptor and a pharmaceutically acceptable carrier, wherein the sensitized T cell-mediated disease is multiple sclerosis, uveitis, chronic thyroiditis, delayed hypersensitivity, contact dermatitis, or atopic dermatitis.

15. (Amended) The method according to claim 14, wherein the antibody directed against the IL-6 receptor is a monoclonal antibody.

16. (Amended) The method according to claim 15, wherein the monoclonal antibody is directed against the human IL-6 receptor.

17. (Amended) The method according to claim 15, wherein the monoclonal antibody is directed against the mouse IL-6 receptor.

C. 18. (Amended) The method according to claim 16, wherein the monoclonal antibody is the PM-1 antibody.

19. (Amended) The method according to claim 17, wherein the monoclonal antibody is the MR16-1 antibody.

20. (Amended) The method according to claim 16, wherein the monoclonal antibody has the constant region of a human antibody.

21. (Amended) The method according to claim 16, wherein the monoclonal antibody is a chimeric or humanized antibody directed against the IL-6 receptor.

22. (Amended) The method according to claim 21, wherein the monoclonal antibody is a humanized PM-1 antibody.

In addition, please add the following new claims 33-38.

33. (New) The method of claim 14, wherein the T cell-mediated disease is multiple sclerosis.

34. (New) The method of claim 14, wherein the T cell-mediated disease is uveitis.

35. (New) The method of claim 14, wherein the T cell-mediated disease is chronic thyroiditis.

36. (New) The method of claim 14, wherein the T cell-mediated disease is delayed hypersensitivity.

37. (New) The method of claim 14, wherein the T cell-mediated disease is contact dermatitis.

38. (New) The method of claim 14, wherein the T cell-mediated disease is atopic dermatitis.